To identify clinical application value of LC3B, we analyzed the effect of LC3B on overall survival (OS) of ovarian cancer patients based on a set of TCGA data, including ovarian cancer patients (n = 311) receiving platinum treatment. Here, MAP1LC3B is linked to ovarian carcinoma.